Innate Pharma S.A.
IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.75
Price+0.29%
$0.00
1Y
Price
Market Cap
$164.331m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.-515.7%
EBITDA Margin-439.2%
Net Profit Margin-642.4%
Free Cash Flow Margin-515.7%
EBITDA Margin-439.2%
Net Profit Margin-642.4%
Free Cash Flow MarginRevenue
$2.787m
+169.7%
1y CAGR+28.0%
3y CAGR+115.0%
5y CAGREarnings
-$49.177m
-61.9%
1y CAGR-176.1%
3y CAGR-134.6%
5y CAGREPS
-$0.53
-60.7%
1y CAGR-183.6%
3y CAGR-144.7%
5y CAGRBook Value
-$21.695m
$62.692m
Assets$84.387m
Liabilities$22.563m
DebtDebt to Assets
36.0%
-0.3x
Debt to EBITDAFree Cash Flow
-$34.910m
-718.5%
1y CAGR-237.2%
3y CAGR-161.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company